SG Americas Securities’s Trillium Therapeutics Inc. TRIL Stock Holding History

SG Americas Securities’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-96,664	Closed	-$1.7M	–	4002
2021 Q3	$1.7M	Buy	+96,664	New	+$1.13M	0.01%	1428
2021 Q1	–	Sell	-27,063	Closed	-$398K	–	3666
2020 Q4	$398K	Buy	27,063 +11,736	+77%	+$169K	﹤0.01%	2159
2020 Q3	$218K	Sell	15,327 -11,441	-43%	-$114K	﹤0.01%	2098
2020 Q2	$217K	Buy	+26,768	New	+$166K	﹤0.01%	2794

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

SG Americas Securities's TRIL Position: Q4 2021 in Review

SG Americas Securities sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 96,664 shares — an estimated $1.7M sold.

SG Americas Securities first reported a position in TRIL in Q2 2020 and held it in 4 quarters. The position peaked at $1.7M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

SG Americas Securities reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
SG Americas Securities sold 96,664 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.7M.
SG Americas Securities first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 4 quarters.
SG Americas Securities's Trillium Therapeutics Inc. position peaked at $1.7M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on SG Americas Securities's 13F filing for Q4 2021, filed 7 Feb 2022.